Repligen Corporation Stock News

WALTHAM, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt

Repligen (RGEN) reports encouraging fourth-quarter results with sales and earnings beating estimates. The company's guidance for 2021 also beats market expectations.

Repligen Corporation's (RGEN) CEO Tony Hunt on Q4 2020 Results - Earnings Call Transcript

Repligen (RGEN) beat estimates for both earnings and revenues in the fourth quarter of 2020.

Shares of Repligen (NASDAQ:RGEN) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share increased 160.00% year over year to $0.52, which beat the estimate of $

WALTHAM, Mass., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f

WALTHAM, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtu

Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Compa

On Repligen's (RGEN) fourth-quarter earnings call, investor focus will be on sales performance of its product franchisees - filtration, chromatography, protein and process analytics.

WALTHAM, Mass. and HALLE (Saale), Germany, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Prot

Repligen (RGEN) closed the most recent trading day at $222.06, moving +1.9% from the previous trading session.

When it comes to coronavirus vaccines, think of Repligen as the man behind the curtain and RGEN stock as a tools powerhouse. Shares broke out of a cup base in January and hover in a buy zone.

Stock market analysis: Nasdaq pullback healthy; SolarEdge, Yatsen IPO dive, Repligen in buy zone. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock

The tailwinds behind the company's gains aren't going anywhere.